Articles tagged with Human Immunodeficiency Virus
In the 48-week SOLO trial, patients taking GW433908/r QD achieved undetectable viral load in 68%, compared to 65% of those taking nelfinavir BID. The study also showed improved efficacy in patients with high or low CD4 counts at baseline.
The study aims to understand the burden of neurological disease in people living with HIV and inform effective management strategies. A cross-sectional study will assess prevalence and features of neurocognitive-behavioral complications, while a subset of patients will be followed over time to monitor health status.
A recent study led by UC Davis finds that syringe-exchange programs significantly reduce HIV risk behavior among injecting drug users. The research shows a two-fold to six-fold reduction in risk behaviors for users with and without access to clean syringes, respectively.
A recent study published in Psychosomatics found that HIV-positive patients who perceive their illness as a 'punishment' experience lower self-esteem and increased depression. The research highlights the need for addressing psychosocial issues, such as punishment beliefs about HIV, on self-care and medical outcomes.
A survey of 299 HIV+ patients found that total pills per day had the greatest impact on adherence, followed by dosing frequency. Patients preferred low-pill-count regimens and those requiring less frequent dosing.
Researchers found that long-term nonprogressors' cells were better able to divide and produce perforin, a molecule that helps kill off infected cells. This discovery is crucial for developing effective vaccines and therapeutic treatments that improve CD8+ T cell function.
Researchers found a significant decrease in new HIV infections among injection drug users in Baltimore between 1988-1990 and 1995-1998, with rates dropping from 4.45% to 1.84%. Higher education, income, marriage, and social support were associated with reduced risk.
Researchers Irwin Chaiken, Nouri Neamati, Alan C. Sartorelli, Nan-Sook Lee, Elias Lolis, and Min Lu received awards for their work on preventing HIV from infecting host cells, developing integrase inhibitors, and making current drugs more effective. The $500,000 award aims to encourage new approaches in HIV/AIDS therapy research.
A phase II study of 100 patients with previously untreated HIV found that kaletra held the virus at undetectable levels for four years, with 72% maintaining suppressed viral loads. The results suggest that Kaletra remains a crucial option for initial therapy, helping to prolong time to resistance development.
A study published in the American Journal of Pathology found that uncircumcised men are more susceptible to HIV due to high concentrations of target cells in their foreskin tissue. This tissue contains higher densities of CD4+ T cells, macropahges and Langerhans' Cells than in circumcised individuals or cervical tissue.
Researchers found that transplant outcomes for HIV patients are similar to those without HIV, but managing anti-rejection drugs and HAART therapy poses a challenge due to potential drug interactions. Studies showed that HIV viral loads remain undetectable in most patients after transplantation.
The Bill & Melinda Gates Foundation is funding a study at UCSF to test diaphragms as an HIV prevention method. The diaphragm holds promise for preventing HIV transmission, particularly in women, who are disproportionately affected by the disease.
Researchers found HIV integrates into human chromosomes near active genes, which are triggered by the virus itself. This targeting specificity could improve gene therapies by leveraging a retrovirus's efficiency.
Two new drugs, Dapivirine and R165335, have shown great promise in Phase I and II clinical trials against drug-resistant HIV strains. These compounds are derived from the dianilinopyrimidine family and have been tested as a viable candidate for treating AIDS in developing countries.
Researchers have identified a natural inhibitor of HIV called CEM15, which can stop the virus from replicating. By targeting Vif, a regulatory protein that enables HIV replication, scientists may develop new antiviral treatments.
Research suggests that social activism in groups like ACT UP can help individuals with AIDS and HIV cope better with their medical and psychological problems. Activist group members tend to use more problem-focused coping, have greater knowledge of treatment information sources, and are more integrated into support networks.
The American Thoracic Society's first issue for August 2002 discusses significant reductions in fatal cardiovascular disease among smokers who quit, with a 50-70% higher hazard rate compared to non-smokers. Additionally, the study reveals improved HIV survival rates, with a marked increase in patients receiving HAART and surviving to h...
A UCLA study found that treating more people in developing countries with antiretroviral drug therapy can eliminate HIV on a community level, even without eradicating it in individuals. The research suggests that treatment and prevention are not two separate approaches, but rather intertwined strategies to save lives.
A recent study found that antiretroviral therapy targeting the central nervous system can improve neurological symptoms in HIV-infected children. The treatment was shown to reduce the amount of virus in their brains and improve developmental milestones.
A team of Los Alamos researchers suggests using a consensus sequence of the HIV-1 virus as a basis for vaccines, rather than geographically specific strains. This approach aims to target common vulnerabilities in multiple strains of the virus.
A retrospective study of 222 patients with HIV found that women experienced higher rates of neurologic complications and lipodystrophy after two years of HAART therapy. The study's findings suggest that while women may respond similarly to treatment as men, they experience more side effects.
A study in Zimbabwe found that women are willing to use diaphragms as a potential HIV prevention method. Diaphragms may increase the effectiveness of new microbicides designed to prevent HIV acquisition, according to principal investigator Nancy Padian.
NIAID-funded studies explore dual protease inhibitors, herpes simplex virus 2 risk factor for HIV infection in India, and anti-HIV antibodies' influence on HIV evolution. The conference also features the world's largest preventive HIV vaccine trial.
Researchers at the University of Pittsburgh discovered that even mild elevations in liver enzymes ALT and AST are associated with a nearly twice higher death rate compared to normal levels. Elevated enzymes signal liver injury and can result from HIV treatment, viral hepatitis, or alcohol abuse.
Researchers found that drug combinations significantly reduced HIV levels in untreated patients, with at least 75% achieving a viral load of less than 400 copies/mL after 48 weeks. The study used three different drug combinations and found impressive changes in viral loads across all groups.
A Johns Hopkins Medicine study reveals that HIV treatment is equally effective for patients with both HIV and hepatitis C infections, contrary to previous assumptions. The research found no significant difference in the virologic or immunologic response to HAART among those with co-infection, suggesting hepatitis C infection should not...
Researchers found that genetic variations in HIV-A and HIV-C proteases make it harder for antiviral drugs to work. The study's findings have negative implications for long-term efficacy of therapies in patients infected with African subtypes.
A pilot study in Uganda found that patients with advanced HIV disease can survive and thrive with antiretroviral therapy. The program implemented an effective system for medical care and drug distribution, resulting in improved adherence to treatment and better virologic responses.
A recent study in rural Uganda found a significant decline in HIV-1 incidence rates between 1990 and 1999, with a notable decrease in the second half of the decade. The reduction was particularly pronounced among men aged 20–24 years and women aged 13–19 years. This finding suggests that targeted interventions may be effective in slowi...
Research suggests African HIV subtypes exhibit higher fitness in protease inhibitors due to natural mutations, leading to faster therapy failure. The findings support broader focus on HIV drug development beyond the B subtype.
Researchers have discovered a new drug combination that outperforms existing treatments in patients with no prior treatment. The lopinavir-ritonavir combination demonstrates superior virus inhibition and reduces the risk of resistance, offering a more convenient regimen for patients.
A long-term pediatric AIDS study of over 500 children reveals that cardiac abnormalities may persist in infants born to HIV-positive mothers. The study found that both infected and uninfected children had higher left ventricle mass and lower contractility, but differences dissipated over time.
The USF team, led by Dr. Jeffrey Nadler, is conducting a national study to assess the safety and ability of an HIV vaccine to stimulate immunity in healthy adults. The vaccine, developed by Merck & Co., uses a prime boost regimen and boosts the activity of killer cells in the immune system to target and kill HIV-infected cells.
The GlaxoSmithKline Drug Discovery and Development Award provides funding for innovative HIV/AIDS research, including therapies aimed at treating infection and preventing transmission. The award is intended to further the development of inventive treatments for HIV/AIDS.
Women in jail have high HIV infection rates, with specific risk factors identified as substance abuse disorders and severe mental illness. An HIV/AIDS education program in a correctional setting has shown promise in reducing the spread of HIV in communities.
According to a University of Pittsburgh study, HIV patients who underwent liver transplantation for hepatitis C virus did not experience further progression of their HIV despite taking immune-suppressing anti-rejection drugs. The study found that all six surviving patients had undetectable HIV viral loads since their transplants.
Researchers found that measles triggers intense immune system activation, temporarily suppressing HIV levels in children. The study suggests a potential clue to understanding HIV pathogenesis and immunity.
A study found that 43% of rural HIV-positive participants engage in elevated risk for transmitting their infection, often due to depression, stress, and lack of access to HIV-prevention programs. Many residents are isolated by the stigma of their illness and lack information about the dangers of unprotected sex.
A second-stage HIV vaccine trial has started in London and Oxford, recruiting 120 volunteers to assess the vaccine's safety and dosage. The trial aims to establish optimum vaccination schedules and booster injections to prevent HIV infection.
A study found that female injection drug users in Vancouver with high-risk behaviors like daily cocaine use and unsafe sex were more likely to convert to HIV. The authors emphasize the need for sex-specific prevention initiatives due to alarming rates of HIV infection among Aboriginal women, twice as high as in non-Aboriginal populations.
A UCLA study found that 75% of HIV-positive women reported a positive change in their views of themselves, while 53% reported a shift in life priorities. The women attributed this change to coping with HIV infection, which made them feel wiser and stronger.
A cross-sectional study of 493 married couples in Thailand found that HIV transmission from men to women is significantly linked to increased viral loads among HIV-positive men. Women who had previously contracted an STD or used hormonal contraceptives were also at higher risk of transmission.
The study found TMC125 effective against highly NNRTI-resistant HIV strains in patients failing treatment. The drug showed no signs of resistance development and was well-tolerated during the trial.
A study found that genetic testing can identify HIV patients at risk of a life-threatening hypersensitive reaction to the antiretroviral drug abacavir. Patients with the HLA-B*5701 allele were over 100 times more likely to experience the adverse reaction.
Researchers found that early in HIV infection, CD8 T cells become unresponsive to HIV surface molecules, suppressing their ability to attack infected cells. This leads to a dominant immunosuppressive response mediated by the molecule TGF-beta.
Researchers found that uncomplicated labor and vaginal delivery do not stimulate the babies' immune systems to HIV infection. Babies born to mothers with chorioamnionitis or preterm labor, however, showed activation of their white blood cells and higher risk of transmission.
Researchers have identified a cholesterol-depleting agent, beta-cyclodextrin, that blocks the transmission of cell-associated HIV. This novel approach targets the migration of white blood cells in semen or cervical mucus carrying HIV and offers a promising method for disease prevention.
A recent analysis of 31 studies found that individuals with HSV-2 infection are twice as likely to contract HIV, with up to half of cases attributed to preceding HSV-2 infection. The study highlights the importance of controlling HSV-2 infection in preventing HIV acquisition.
Researchers found a significant link between sarcoidosis and family history, with affected individuals more likely to have siblings or parents with the disease. Air pollution during adolescence also affects lung function growth and performance, while improved HIV treatment reduces the risk of pulmonary complications.
Researchers suggest a structured intermittent therapy approach, where patients receive daily doses of HAART for seven days, followed by seven days off the medication. This regimen has shown significant reductions in certain side effects, including cholesterol and triglyceride levels, without compromising treatment efficacy.
Researchers have developed optimized antiviral peptide vaccines that exhibit enhanced efficacy against various viral infections, including HIV and SARS-CoV-2. These improvements are attributed to the incorporation of specific amino acid sequences that enhance immune responses.
A questionnaire surveyed junior doctors in two London teaching hospitals and found that nearly all were aware of post-exposure prophylaxis (PEP) but many lacked knowledge on its use. The study highlights the need for improved education on PEP among medical professionals to prevent occupationally acquired HIV infections.
A recent study by Ohio State University researchers found that gay men tend to weigh the benefits and drawbacks of revealing their HIV status, with over half disclosing to family and 63% telling friends. The top reasons for disclosure included keeping others safe and seeking understanding.
Researchers find HIV attachment to rafts is crucial for replication, and cholesterol-lowering drugs may help disrupt this process. Depleting cholesterol from rafts using compounds significantly reduces HIV's ability to infect new cells.
Researchers at Jefferson Medical College have demonstrated in the laboratory that prostratin can stimulate two main hiding areas in patients with HIV infection who are taking HAART, leading to death of the virus from anti-viral drugs. The work shows promise for a new second-generation approach to eradicate HIV from the body.
A survey of 310 pregnant women in Zambia found that 74% prefer targeted therapy with resources available, while 60% support mass drug administration if only half the population is targeted. The results suggest that most women would prioritize access to nevirapine over testing.
A study published in The Lancet found that HIV-positive women can shed the virus in their genital tracts even when their blood levels are low, posing a risk of transmission to others. The researchers analyzed samples from 311 HIV-positive women and found that about a third had HIV-1 shedding in their genital region.
Researchers at Gladstone Institute of Virology and Immunology found that HIV's Vpr gene causes the formation of nuclear herniations, disrupting cell division. This disruption enables virus production to increase severalfold, improving HIV's ability to grow and infect new cells.
Researchers found that HHV-6 inhibits early-stage HIV variants by blocking CCR5 receptors, slowing their reproduction. The harmless herpesvirus may create favorable conditions for later-stage HIV variants that use CXCR4 receptors.
A Yale study found that HIV patients who trust their physicians are 20% more likely to adhere to their treatment regimens. Lack of social support and mistrust in peers also hinder adherence to ART.